OTC: ADIA · Life Sciences · 5 alerts · CIK 1160420
Share price
$0.1280Close, Nov 13
Market cap
$12.1M
Shares outstanding
94.4MLatest SEC cover page
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Adia Med, Inc. filings on SEC EDGAR ↗
Adia Med, Inc. reported total revenue of $1,019,245 for the nine months ended September 30, 2026, a significant increase from $521,958 in the prior year, driven primarily by medical procedures and biologics sales. Despite the revenue growth, the company realized a net loss of $271,922 for the period as operating expenses, particularly legal and professional fees and salaries, increased substantially.
Adia Med, Inc. entered into a Membership Interest Purchase Agreement to sell a 7% membership interest in its subsidiary, Adia Labs LLC, to the company's CEO, Larry A. Powalisz. The transaction is valued at $350,000 in cash, with the use of proceeds restricted to corporate purposes jointly approved by the company's independent directors.
Adia Med, Inc. fully repaid and discharged its $1.0 million unsecured revolving line of credit facility with its CEO, Larry Powalisz. The company made two payments totaling $934,970.94, which included $74,658.94 in accrued interest, to satisfy the debt in full. This related-party facility, originally entered into in June 2024, is now terminated following the final payment on October 9, 2026.
Adia Med Divestiture to Live Oak Health LLC for $1.5M
Adia Med, Inc. entered into a Membership Interest Purchase Agreement to sell a 30% interest in its subsidiary, Adia Labs LLC, to Live Oak Health LLC (dba QCM Biologics) for $1.5 million. The consideration consists of $1.0 million in cash and a $0.5 million promissory note, with the buyer also receiving an option to purchase an additional 10% stake for $0.5 million. Despite the minority equity sale, the agreement establishes equal 50/50 voting power between Adia Med and the buyer regarding member matters.
Adia Med, Inc. filed a declaratory judgment lawsuit in Florida against Tydus Richards and other purported shareholders to quiet title in 29,059,792 shares of common stock. The company alleges the shares, representing approximately 30.78% of its outstanding stock, were never validly issued or paid for. If successful, the action would allow the company to cancel and retire these shares, significantly reducing its total share count.